Emilio Medina-Rivero

Dr. Emilio Medina-Rivero

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2015 in Biotechnology Reports
Verified
Journal Article
Open access
DCDaniela Cadena-Herrera
Daniela Cadena-Herrera
JLJoshua E. Esparza-De Lara
Joshua E. Esparza-De Lara
NRNancy D. Ramírez-Ibañez
Nancy D. Ramírez-Ibañez
CLCarlos A. López-Morales
Carlos A. López-Morales
NPNestor O. Octavio Perez
Nestor O. Octavio Perez
EMEmilio Medina-Rivero
Emilio Medina-Rivero
A viable cell count is essential to evaluate the kinetics of cell growth. Since the hemocytometer was first used for counting blood cells, several variants of the methodology have been developed towards reducing the time of analysis and improving accuracy through automation of both sample preparation and counting. The successful implementation of automated techniques relies in the adjustment of cell staining, image display parameters and cell morphology to obtain equivalent precision, accuracy and linearity with respect to the hemocytometer. In this study we conducted the validation of three trypan blue exclusion-based methods: manual, semi-automated, and fully automated; which were used for the estimation of density and viability of cells employed for the biosynthesis and bioassays of recombinant proteins. Our results showed that the evaluated attributes remained within the same range for the automated methods with respect to the manual, providing an efficient alternative for analyzing a huge number of samples.

1 January 2016 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
RARodrigo Arreola
Rodrigo Arreola
Priscila Samantha Alvarez-HerreraPriscila Samantha Alvarez-Herrera
Priscila Samantha Alvarez-Herrera
Gilberto Pérez--SánchezGilberto Pérez--Sánchez
Gilberto Pérez--Sánchez
Enrique Becerril VillanuevaEnrique Becerril Villanueva
Enrique Becerril Villanueva
CCCarlos Cruz-Fuentes
Carlos Cruz-Fuentes
Lenin PavónLenin Pavón
Lenin Pavón
Dopamine (DA), a neurotransmitter in the central nervous system (CNS), has modulatory functions at the systemic level. The peripheral and central nervous systems have independent dopaminergic system (DAS) that share mechanisms and molecular machinery. In the past century, experimental evidence has accumulated on the proteins knowledge that is involved in the synthesis, reuptake, and transportation of DA in leukocytes and the differential expression of the D1-like(D1R and D5R) and D2-likereceptors (D2R, D3R, and D4R). The expression of these components depends on the state of cellular activation and the concentration and time of exposure to DA. Receptors that are expressed in leukocytes are linked to signaling pathways that are mediated by changes in cAMP concentration, which in turn triggers changes in phenotype and cellular function. According to the leukocyte lineage, the effects of DA are associated with such processes as respiratory burst, cytokine and antibody secretion, chemotaxis, apoptosis, and cytotoxicity. In clinical conditions such as schizophrenia, Parkinson disease, Tourette syndrome, and multiple sclerosis (MS), there are evident alterations during immune responses in leukocytes, in which changes in DA receptor density have been observed. Several groups have proposed that these findings are useful in establishing clinical status and clinical markers.

18 February 2013 in Electrophoresis
Verified
Journal Article
Closed access
PDF file
CGCarlos E. Espinosa‐ de la Garza
Carlos E. Espinosa‐ de la Garza
FPFrancisco C. Perdomo‐Abúndez
Francisco C. Perdomo‐Abúndez
JPJesús Padilla‐Calderón
Jesús Padilla‐Calderón
JUJaime M. Uribe‐Wiechers
Jaime M. Uribe‐Wiechers
NPNestor O. Octavio Perez
Nestor O. Octavio Perez
EMEmilio Medina-Rivero
Emilio Medina-Rivero

21 April 2011 in Bulletin of Environmental Contamination and Toxicology
Verified
Journal Article
Closed access
PDF file
MGM. I. González-Castro
M. I. González-Castro
FOFatima Olea-Serrano
Fatima Olea-Serrano
ARA. M. Rivas-Velasco
A. M. Rivas-Velasco
EMEmilio Medina-Rivero
Emilio Medina-Rivero
LOLeandro G. Ordoñez-Acevedo
Leandro G. Ordoñez-Acevedo
ARAntonio De Leon Rodriguez
Antonio De Leon Rodriguez

1 June 2007 in Biomolecular Engineering
Verified
Journal Article
Closed access
LMLuz M.T. Paz Maldonado
Luz M.T. Paz Maldonado
VHVíctor E. Balderas Hernández
Víctor E. Balderas Hernández
EMEmilio Medina-Rivero
Emilio Medina-Rivero
ARAna P. Barba de la Rosa
Ana P. Barba de la Rosa
JFJosé L. Flores Flores
José L. Flores Flores
ARAntonio De Leon Rodriguez
Antonio De Leon Rodriguez

1 January 2014 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Open access
EMEmilio Medina-Rivero
Emilio Medina-Rivero
GMGiovanna Merchand-Reyes
Giovanna Merchand-Reyes
Lenin PavónLenin Pavón
Lenin Pavón
SVSaid Vázquez-Leyva
Said Vázquez-Leyva
Gilberto Pérez--SánchezGilberto Pérez--Sánchez
Gilberto Pérez--Sánchez
SPSonia Mayra Pérez-Tapia
Sonia Mayra Pérez-Tapia
Human dialyzable leukocyte extracts (DLEs) are heterogeneous mixtures of low-molecular-weight peptides that modulate immune responses in various diseases. Due their complexity, standardized methods to identify their physicochemical properties and determine that production batches are biologically active must be established. We aimed to develop and validate a size exclusion ultra performance chromatographic (SE-UPLC) method to characterize Transferon™, a DLE that is produced under good manufacturing practices (GMPs). We analyzed an internal human DLE standard and 10 representative batches of Transferon™, all of which had a chromatographic profile characterized by 8 main peaks and a molecular weight range between 17.0 and 0.2kDa. There was high homogeneity between batches with regard to retention times and area percentages, varying by less than 0.2% and 30%, respectively, and the control chart was within 3 standard deviations. To analyze the biological activity of the batches, we studied the ability of Transferon™ to stimulate IFN-γ production in vitro. Transferon™ consistently induced IFN-γ production in Jurkat cells, demonstrating that this method can be included as a quality control step in releasing Transferon™ batches. Because all analyzed batches complied with the quality attributes that were evaluated, we conclude that the DLE Transferon™ is produced with high homogeneity.